Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 17, 1999

View Archived Issues

New data reported on thalidomide for several cancer indications

Preclinical data highlight Xcytrin's anticancer activity and novel mechanism of action

Vical updates product pipeline

StressGen to codevelop HspE7 with NCI for HPV diseases

OGS renegotiates license agreement with Searle for OGT-918

Ontogen completes phase I multidose oral study of MDR compound

InSite Vision licenses glaucoma diagnosis technology to Pharmacia & Upjohn

GelTex and Sankyo sign letter of intent for marketing CholestaGel and second-generation product

Preclinical data presented at AHA support promising profile of V-20

Vioxx now available in Canada for treatment of osteoarthritis

Optimal timing of cardiac imaging with 99mTc-NOET

Kinase inhibitors developed at Boehringer Ingelheim as potential anticancer agents

Another series of dopamine agonists for schizophrenia, Parkinson's disease from AHP

Pfizer's new MMP inhibitors selective for MMP-13 and/or TACE

New benzamides for CNS disorders, particularly epilepsy, presented by SB

Merck synthesizes novel oxytocin receptor antagonists with piperazine structure

Pharmaceutical agents useful as vitronectin antagonists and methods of use

Sumitomo's SM-13496: further clinical development may be handled overseas

Rheumatology update: two-year leflunomide data support sustained efficacy and safety

Ajinomoto expands European and U.S. development efforts

Sonus restructures EchoGen marketing agreement with Abbott

Lotronex recommended for approval by FDA advisory committee as IBS treatment

Hoe-140 effective against joint but not intestinal inflammation in rat model

Small patient study indicates potential new indication for leflunomide

Complement inhibitor 5G1.1 reduces signs and symptoms of RA in patient study

Foscan receives orphan drug designation in U.S.; MAA accepted in E.U.

Lorus files IND seeking clearance for phase I/II clinical trials of GTI-2040

Effects of IL-10 agonist IT-9302 on immunological markers in acute necrotizing pancreatitis

RPR/INGN-201 + radiotherapy provides supraadditive effects in prostate cancer xenograft models

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 21, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...